公开(公告)号：US12077606B2

公开(公告)日：2024-09-03

申请号：US17560105

申请日：2021-12-22

Applicant: Sirenas LLC

Inventor： Ippei Usui ,  Bryan Junn Lee ,  Steven Bruce Cohen ,  Venkat Rami Reddy Macherla ,  Jacob Neal Beverage ,  Chung-Mao Pan ,  Farhana Barmare ,  Eduardo Esquenazi

IPC: C07K11/02 ,  A61K38/08 ,  A61K47/68 ,  A61P35/00 ,  C07K7/06 ,  C07K16/32 ,  A61K38/00 ,  C07K16/00

CPC classification number: C07K7/06 ,  A61K38/08 ,  A61K47/6811 ,  A61K47/6855 ,  A61K47/6889 ,  A61P35/00 ,  C07K16/32 ,  A61K38/00 ,  C07K16/00 ,  C07K2319/00

Abstract: Provided are cyclic peptide analogs, conjugates comprising such compounds, and pharmaceutical compositions comprising such compounds and conjugates, and methods of treating cancer with such compounds and conjugates.

公开(公告)号：US20240279325A1

公开(公告)日：2024-08-22

申请号：US18480730

申请日：2023-10-04

Applicant: Chugai Seiyaku Kabushiki Kaisha

Inventor： Tomoyuki Igawa ,  Atsuhiko Maeda ,  Shigero Tamba ,  Takeshisa Kitazawa ,  Takeshi Baba ,  Yoshinao Ruike ,  Junichi Nezu

IPC: C07K16/24 ,  A61K39/00 ,  C07K16/00 ,  C07K16/18 ,  C07K16/22 ,  C07K16/28

CPC classification number: C07K16/24 ,  C07K16/00 ,  C07K16/18 ,  C07K16/22 ,  C07K16/248 ,  C07K16/2866 ,  A61K2039/505 ,  C07K2317/20 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/64 ,  C07K2317/70 ,  C07K2317/71 ,  C07K2317/72 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

Abstract: The present inventors newly discovered that even if an antigen-binding molecule inhibits in vitro some of the physiological activities of an antigen having two or more physiological activities without inhibiting the remaining physiological activities, the molecule can promote elimination of the antigen from blood (from serum or plasma) and as a result reduce the physiological activities in vivo, when the antigen-binding molecule is conferred with the properties: (i) of binding to human FcRn under an acidic pH range condition; (ii) of binding under a neutral pH range condition to human Fc receptor stronger than native human IgG, and (iii) that its antigen-binding activity alters according to the ion concentration.

公开(公告)号：US20240279314A1

公开(公告)日：2024-08-22

申请号：US18618981

申请日：2024-03-27

Applicant: The Rockefeller University

Inventor： Jeffrey Ravetch ,  Falk Nimmerjahn ,  Yoshikatsu Kaneko

IPC: C07K16/00 ,  A61K39/00 ,  A61K47/68 ,  C07K16/06 ,  C07K16/18 ,  C12P21/00 ,  G01N33/68

CPC classification number: C07K16/00 ,  A61K47/68 ,  C07K16/06 ,  C07K16/18 ,  C12P21/005 ,  G01N33/6854 ,  A61K2039/505 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/71 ,  C07K2317/76

Abstract: The invention provides a polypeptide containing at least one IgG Fc region, wherein said at least one IgG Fc region is glycosylated with at least one galactose moiety connected to a respective terminal sialic acid moiety by a α 2,6 linkage, and wherein said polypeptide having a higher anti-inflammatory activity as compared to an unpurified antibody.

公开(公告)号：US20240271127A1

公开(公告)日：2024-08-15

申请号：US17784796

申请日：2020-12-15

Applicant: Aridis Pharmaceuticals, Inc.

Inventor： Kathy Ngo ,  Jennifer Woo ,  Binh Pham ,  Vu Truong-Le

IPC: C12N15/11 ,  C07K16/00 ,  C12N5/071 ,  C12N9/22

CPC classification number: C12N15/111 ,  C07K16/00 ,  C12N5/0682 ,  C12N9/22 ,  C07K2317/14 ,  C12N2310/20

Abstract: This application describes cells, systems, and molecular engineering methods using CRISPR/Cas complexes for targeted activation of endogenous master transcriptional regulatory elements (MTRE) such as PRDM1, XBP1 and IRF4, to generate high productivity antibody production in production cell lines such as CHO and NSO cells. These incorporate the inclusion of the Cas accessory proteins, design of multiple guide RNAs (gRNA), and unique multiplexing of these components using, e.g., lentiviral transfection to induce increased transcription and translation of antibody genes under the control of the MTRE. The methods result in synergies increasing monoclonal antibody production by these modified cell lines. While a significant increase in productivity is demonstrated by this method of activation, further increase in productivity can be accomplished by genetic transfer of additional copies of MTREs.

公开(公告)号：US12054751B2

公开(公告)日：2024-08-06

申请号：US18066303

申请日：2022-12-15

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Gang Chen ,  Darya Burakov ,  James P. Fandl

IPC: C12N9/04 ,  C12N15/00 ,  C12P21/00 ,  C12P21/04 ,  C07K16/00 ,  C07K16/28

CPC classification number: C12N9/0006 ,  C12N15/00 ,  C12P21/005 ,  C12Y101/01271 ,  C07K16/00 ,  C07K16/2863 ,  C07K16/2866 ,  C07K2317/14 ,  C07K2317/41 ,  Y02P20/52

Abstract: An isolated nucleic acid encoding an FX protein having a serine at position 79, a lysine at position 90, a leucine at position 136, an arginine at position 211, a serine at position 289, and a combination thereof is provided. Cells having a gene encoding a modified FX protein are provided, wherein the cells exhibit a reduced ability to fucosylate a glycoprotein at a first temperature, but exhibit the ability to fucosylate the glycoprotein at a second temperature. Methods and compositions for making glycoproteins with reduced fucosylation are provided.

公开(公告)号：US12049516B2

公开(公告)日：2024-07-30

申请号：US16849847

申请日：2020-04-15

Applicant: TRIANNI, INC.

Inventor： Matthias Wabl

IPC: C07K16/46 ,  A01K67/0278 ,  C07K16/00 ,  A61K39/00

CPC classification number: C07K16/462 ,  A01K67/0278 ,  C07K16/00 ,  C12Y304/24046 ,  A01K2217/072 ,  A01K2217/15 ,  A01K2227/105 ,  A61K2039/552 ,  C07K2317/20 ,  C07K2317/24 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/56

Abstract: The present invention relates to transgenic mammals that express canine-based immunoglobulins, including transgenic rodents that express canine-based immunoglobulins for the development of canine therapeutic antibodies.

公开(公告)号：US20240247050A1

公开(公告)日：2024-07-25

申请号：US18290024

申请日：2022-05-09

Applicant: UCB BIOPHARMA SRL

Inventor： GEOFFREY NORMAN BROWN ,  RICHARD BARRY DAVIES

IPC: C07K16/00

CPC classification number: C07K16/00 ,  C07K2317/14

Abstract: The invention relates to the field of recombinant production of proteins in bacterial host cells. In particular, the invention relates to processes for culturing bacterial host cells for the production of recombinant proteins, wherein the formation of struvite is reduced by keeping the amount of magnesium added during the production phase within particular ranges.

公开(公告)号：US20240240173A1

公开(公告)日：2024-07-18

申请号：US18529287

申请日：2023-12-05

Applicant: The Board of Trustees of the Leland Stanford Junior University ,  The United States Government as Represented by the Department of Veterans Affairs

Inventor： William H. Robinson ,  Yann Chong Tan ,  Jeremy Sokolove

IPC: C12N15/10 ,  C07K16/00 ,  C07K16/12 ,  G01N33/68

CPC classification number: C12N15/1065 ,  C07K16/00 ,  C07K16/1242 ,  C07K16/1271 ,  G01N33/6854 ,  C07K2317/21 ,  C07K2317/76 ,  G01N2458/10 ,  G01N2500/00

Abstract: Disclosed herein are compositions and methods for sequencing, analyzing, and utilizing samples such as single samples. Also disclosed herein are compositions and methods for matching together two or more sequences from a sample. Also disclosed herein are compositions and methods for expressing and screening molecules of interest.

公开(公告)号：US12024560B2

公开(公告)日：2024-07-02

申请号：US16498784

申请日：2018-03-28

Applicant: LYVGEN BIOPHARMA HOLDINGS LIMITED

Inventor： Jieyi Wang

IPC: C07K16/28 ,  A61K38/18 ,  A61K39/00 ,  A61P37/04 ,  C07K14/705 ,  C07K16/00

CPC classification number: C07K16/283 ,  A61K38/1825 ,  A61P37/04 ,  A61K2039/505 ,  C07K14/70503 ,  C07K16/00 ,  C07K2317/50 ,  C07K2317/52

Abstract: Human IgG1, IgG2, and IgG4 mutants having mutations in the hinge domain and exhibiting altered binding activity to Fcγ receptors such as FcγRIIB (CD32B). Also provided herein are methods for selectively activating immune responses in a subject using a therapeutic agent capable of targeting both an immune cell surface receptor and FcγRIIB.

公开(公告)号：US12024548B2

公开(公告)日：2024-07-02

申请号：US16244909

申请日：2019-01-10

Applicant: Hoffmann-La Roche Inc.

Inventor： Simone Dethloff ,  Erhard Kopetzki ,  Dominique Ostler ,  Stefan Seeber ,  Georg Tiefenthaler

IPC: C12N15/85 ,  C07K16/00 ,  C12N5/0781 ,  C12N15/10 ,  C12P21/02

CPC classification number: C07K16/00 ,  C12N5/0635 ,  C12N15/1086 ,  C12N15/85 ,  C12P21/02 ,  C07K2317/14 ,  C07K2317/56 ,  C12N2510/02 ,  C12N15/1086 ,  C12Q2521/507 ,  C12Q2537/143

Abstract: In the method as reported herein the isolation of nucleic acid segments encoding antibody variable domains and the insertion of the isolated nucleic acid segments in eukaryotic expression plasmids is performed without the intermediate isolation and analysis of clonal intermediate plasmids. Thus, in the method as reported herein the intermediate cloning, isolation and analysis of intermediate plasmids is not required, e.g. by analysis of isolated transformed E. coli cells.